Author

Bing Liu

Observed name: B. Liu

Institutions: Shanghai University, Nanjing Children's Hospital, Second Affiliated Hospital of Nanjing Medical University, Nanjing Medical University

Observed institutions: Qingdao University, Shanghai University, Sheng Jing Hospital, Nanjing Children's Hospital, Affiliated Hospital of Qingdao University, Second Affiliated Hospital of Nanjing Medical University, Nanjing Medical University, China Medical University

ORCID: 0009-0004-7639-8235

Observed ORCID: 0009-0004-7639-8235

OpenAlex ID: A5013425792

Physical Exercise: A Promising Treatment Against Organ Fibrosis

2025 · Xiaojie Ma, Bing Liu, et al. · International Journal of Molecular Sciences · 14

Assessing of programmed cell death gene signature for predicting ovarian cancer prognosis and treatment response

2023 · Xin Lian, Bing Liu, et al. · Frontiers in Endocrinology · 6

Nanomicrosphere sustained-release urokinase systems with antioxidant properties for deep vein thrombosis therapy

2024 · Shun Xiao, Xiaozhi Sun, et al. · RSC Advances · 5

CoS 1.097 nanocrystals as new nanoplatforms for photothermal therapy of arterial inflammation

2024 · Ran Lu, Zaiman Ge, et al. · RSC Advances · 2

Endothelial MicroRNA-214 Confers Angiotensin II Hypertension by Targeting eNOS in Mice

2025 · Shuzhen Li, Bing Liu, et al. · Kidney & Blood Pressure Research · 1

P591: Preliminary Results of a Phase I Study of Clifutinib, a Highly Selective, Potent Oral Flt-3 Inhibitor, in Patinets With Flt3-mutated Relapsed or Refractory Acute Myeloid Leukemia

2022 · W. Yu, X. Wei, et al. · HemaSphere · 1

Works count: 6

Citation count: 29

H-index: 3

I10-index: 1